Johnson & Johnson (NYSE:JNJ) Shares Bought by Continuum Advisory LLC

Continuum Advisory LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 1.8% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 8,396 shares of the company’s stock after acquiring an additional 152 shares during the quarter. Continuum Advisory LLC’s holdings in Johnson & Johnson were worth $1,227,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of JNJ. Accredited Investors Inc. raised its position in shares of Johnson & Johnson by 5.1% during the 2nd quarter. Accredited Investors Inc. now owns 7,600 shares of the company’s stock worth $1,111,000 after purchasing an additional 369 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its position in shares of Johnson & Johnson by 1.6% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 2,621,020 shares of the company’s stock valued at $383,088,000 after buying an additional 41,492 shares during the last quarter. Sara Bay Financial increased its stake in Johnson & Johnson by 8.8% in the second quarter. Sara Bay Financial now owns 2,971 shares of the company’s stock valued at $434,000 after purchasing an additional 240 shares during the last quarter. Meridian Investment Counsel Inc. lifted its position in Johnson & Johnson by 3.6% during the second quarter. Meridian Investment Counsel Inc. now owns 18,919 shares of the company’s stock worth $2,765,000 after buying an additional 653 shares during the period. Finally, Altus Wealth Management LLC boosted its stake in Johnson & Johnson by 8.9% in the 2nd quarter. Altus Wealth Management LLC now owns 1,690 shares of the company’s stock worth $247,000 after buying an additional 138 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.6 %

NYSE:JNJ traded up $0.91 during trading hours on Tuesday, hitting $160.54. The stock had a trading volume of 2,143,439 shares, compared to its average volume of 7,290,531. The business has a 50 day simple moving average of $152.63 and a two-hundred day simple moving average of $153.07. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $169.85. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. The company has a market cap of $386.37 billion, a PE ratio of 9.95, a price-to-earnings-growth ratio of 2.63 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.71 by $0.11. The firm had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm’s quarterly revenue was up 4.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.80 EPS. Analysts predict that Johnson & Johnson will post 10.07 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.09%. The ex-dividend date of this dividend is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on JNJ. The Goldman Sachs Group cut their price objective on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a report on Friday, July 19th. Daiwa America lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Monday, August 5th. TD Securities reduced their target price on Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Finally, Morgan Stanley upped their price target on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 18th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $173.21.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.